Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Mirvetuximab Soravtansine

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Humov 19, Unii-98de7vn88d, Imgn853, Imgn 853, Mirvetuximab soravtansine [usan], Mirvetuximab-soravtansine
    Molecular Formula
    C42H61ClN4O14S3
    Molecular Weight
    977.6  g/mol
    InChI Key
    ZOHXWSHGANNQGO-DSIKUUPMSA-N
    Mirvetuximab Soravtansine is an immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) conjugated, via the disulfide-containing cleavable linker sulfo-SPDB, to the cytotoxic maytansinoid DM4, with potential antineoplastic activity. The anti-FOLR1 monoclonal antibody moiety of mirvetuximab soravtansine targets and binds to the cell surface antigen FOLR1. After antibody-antigen interaction and internalization, the immunoconjugate releases DM4, which binds to tubulin and disrupts microtubule assembly/disassembly dynamics, thereby inhibiting cell division and cell growth of FOLR1-expressing tumor cells. FOLR1, a member of the folate receptor family is overexpressed on a variety of epithelial-derived cancer cells. The sulfo-SPDB linker prevents cleavage in the bloodstream and may improve this agent's efficacy in multidrug resistant tumor cells.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-amino-4-[[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.110,14.03,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy]-1-oxopropan-2-yl]-methylamino]-2-methyl-5-oxopentan-2-yl]disulfanyl]-1-oxobutane-2-sulfonic acid
    2.1.2 InChI
    InChI=1S/C42H61ClN4O14S3/c1-23-12-11-13-31(58-10)42(53)22-29(59-39(52)45-42)24(2)36-41(6,61-36)32(21-34(49)47(8)27-19-26(18-23)20-28(57-9)35(27)43)60-38(51)25(3)46(7)33(48)14-16-40(4,5)63-62-17-15-30(37(44)50)64(54,55)56/h11-13,19-20,24-25,29-32,36,53H,14-18,21-22H2,1-10H3,(H2,44,50)(H,45,52)(H,54,55,56)/b13-11+,23-12+/t24-,25+,29+,30?,31-,32+,36+,41+,42+/m1/s1
    2.1.3 InChI Key
    ZOHXWSHGANNQGO-DSIKUUPMSA-N
    2.1.4 Canonical SMILES
    CC1C2CC(C(C=CC=C(CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)CC(C4(C1O4)C)OC(=O)C(C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)C)OC)(NC(=O)O2)O
    2.1.5 Isomeric SMILES
    C[C@@H]1[C@@H]2C[C@]([C@@H](/C=C/C=C(/CC3=CC(=C(C(=C3)OC)Cl)N(C(=O)C[C@@H]([C@]4([C@H]1O4)C)OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(=O)N)S(=O)(=O)O)C)\C)OC)(NC(=O)O2)O
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. Imgn-853

    2. Imgn853

    2.2.2 Depositor-Supplied Synonyms

    1. Humov 19

    2. Unii-98de7vn88d

    3. Imgn853

    4. Imgn 853

    5. Mirvetuximab Soravtansine [usan]

    6. Mirvetuximab-soravtansine

    7. 98de7vn88d

    8. Imgn-853

    9. Schembl16447449

    10. 1453084-37-1

    11. Immunoglobulin G1, Anti-(human Folate Receptor Alpha) (human-mus Musculus Monoclonal M9346a Heavy Chain), Disulfide With Human-mus Musculus Monoclonal M9346a Light Chain, Dimer, Tetraamide With N2'-(4-((3-carboxy-3-sulfopropyl)dithio)-4-methyl-1-oxopentyl)-n2'-deacetylmaytansine

    12. Q27272114

    2.3 Create Date
    2015-07-11
    3 Chemical and Physical Properties
    Molecular Weight 977.6 g/mol
    Molecular Formula C42H61ClN4O14S3
    XLogP31.8
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count16
    Rotatable Bond Count16
    Exact Mass976.3034938 g/mol
    Monoisotopic Mass976.3034938 g/mol
    Topological Polar Surface Area313 Ų
    Heavy Atom Count64
    Formal Charge0
    Complexity1890
    Isotope Atom Count0
    Defined Atom Stereocenter Count8
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count2
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of fallopian tube cancer , Treatment of ovarian carcinoma, Treatment of peritoneal carcinoma